- Trials with a EudraCT protocol (83)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
83 result(s) found for: Serum Protein Electrophoresis.
Displaying page 1 of 5.
EudraCT Number: 2014-000268-17 | Sponsor Protocol Number: CC-4047-MM-007 | Start Date*: 2015-04-02 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJEC... | |||||||||||||
Medical condition: relapsed or refractory multiple myeloma (MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NO (Completed) DK (Completed) SE (Completed) FI (Completed) ES (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003517-95 | Sponsor Protocol Number: OP-103 | Start Date*: 2017-01-31 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to... | |||||||||||||
Medical condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Temporarily Halted) BE (Completed) DK (Completed) NL (Completed) NO (Completed) FR (Ongoing) PL (Completed) AT (Completed) EE (Completed) LT (Completed) IT (Ongoing) RO (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000431-49 | Sponsor Protocol Number: CC220MM002 | Start Date*: 2021-10-18 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Ongoing) PT (Ongoing) FI (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) GR (Ongoing) IE (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001737-27 | Sponsor Protocol Number: 54767414AMY3001 | Start Date*: 2018-04-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos... | |||||||||||||
Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) SE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004823-39 | Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 | Start Date*: 2008-04-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK... | |||||||||||||
Medical condition: Previously untreated multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021146-22 | Sponsor Protocol Number: 5339 | Start Date*: 2012-10-23 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Alemtuzumab and rheumatoid arthritis - an immunisation study | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001563-21 | Sponsor Protocol Number: IM-T-hLL2-18 | Start Date*: 2005-02-02 |
Sponsor Name:Immunomedics, Inc. | ||
Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005384-16 | Sponsor Protocol Number: FLORAMICAR | Start Date*: 2016-04-26 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl... | ||||||||||||||||||
Medical condition: Patients with high clinical suspicion of cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001052-39 | Sponsor Protocol Number: ARRAY-520-311 | Start Date*: 2014-11-02 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus ... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006050-10 | Sponsor Protocol Number: 26866138-MMY-2043 | Start Date*: 2007-09-18 |
Sponsor Name:Janssen-Cilag International, N.V.Turnhoutseweg 30, 2340 Beerse, Belgium | ||
Full Title: A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untre... | ||
Medical condition: Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) AT (Completed) HU (Completed) PT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004664-18 | Sponsor Protocol Number: NEOD001-OLE251 | Start Date*: 2017-08-08 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO) | |||||||||||||
Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012136-33 | Sponsor Protocol Number: IPH2101-201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: Open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two different dose regimens of IPH 2101, a human monoclonal anti-KIR antibody, in patients with multip... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002169-14 | Sponsor Protocol Number: TAK-573-2001 | Start Date*: 2023-03-10 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With... | ||
Medical condition: Multiple Myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002161-36 | Sponsor Protocol Number: OP-108 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma | |||||||||||||
Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001023-38 | Sponsor Protocol Number: bb2121-MM-003 | Start Date*: 2019-05-13 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (... | ||||||||||||||||||
Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) DE (Ongoing) BE (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015507-52 | Sponsor Protocol Number: CLBH589D2308 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003486-58 | Sponsor Protocol Number: 2007-03 | Start Date*: 2009-01-26 | |||||||||||
Sponsor Name:Intergroupe Francophone du Myélome | |||||||||||||
Full Title: Pharmacogenomic study to predict survival, best response and toxicity in newly diagnosed myeloma patients who are either 65 years of age or older treated with either a combination of melphalan-pred... | |||||||||||||
Medical condition: Patients aged 65 and over, suffering of previously untreated symptomatic multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000750-66 | Sponsor Protocol Number: 12-02 | Start Date*: 2013-07-02 | |||||||||||
Sponsor Name:ICORG-the All Ireland Co-operative Oncology Research Group | |||||||||||||
Full Title: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Asymptomatic High-Risk Smoldering Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004315-31 | Sponsor Protocol Number: O-12-M1 | Start Date*: 2013-04-10 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed and/or Relapsed-Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000748-14 | Sponsor Protocol Number: H6Q-MC-S042 | Start Date*: 2008-05-30 |
Sponsor Name:Eli Lilly and Company limited | ||
Full Title: An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom’s Macroglobulinemia or Multiple Myeloma | ||
Medical condition: Waldenstrom’s Macroglobulinemia or Multiple Myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.